$1.88 -0.04 (-2.08%)
12/3/2009 4:00 PM

Ligand Pharmaceuticals, Inc. (LGND )

CAPS Rating: 3 out of 5

Develops and markets new drugs that address critical unmet medical needs in the areas of cancer, mens and womens health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases.

Current Price $1.88 Mkt Cap $212.47M
Open $0.00 P/E Ratio 0.00
Prev. Close $1.92 Div. (Yield) N/A (N/A)
Daily Range $1.87 - $2.02 Volume 696,054
52-Wk Range $1.63 - $3.21 Avg. Daily Vol. 598,000

LGND News and Commentary

Caps

How do you think LGND will perform vs the S&P 500?

Add Stock to Watchlist

All Members

129 Outperform
17 Underperform
 

All-Star Members

44 Outperform
5 Underperform
 

Wall Street

5 Outperform
1 Underperform
 

Top LGND Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.57)
Submitted April 14, 2009

I've been looking for a bigger pullback in Ligand given weak knees in the past but I'm getting tired of standing on the sidelines as the company continues to progress its pipeline. Mixed news on Fablyn since my last pitch - a Complete Response from… More

0 Comments | Reply | Report this Post

ImmortalThanos (72.63)
Submitted February 28, 2008

Avoid this like the plague. This is another one of those "Jack Of All Trades" companies that never really gets anywhere. Skip this until they get a better mission statement developed.

0 Comments | Reply | Report this Post
LGND VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about LGND .

Recs

0
Member Avatar topsecret09 (20.42) Submitted: 11/29/2009 11:35:42 AM : Outperform Start Price: $1.93 LGND Score: -3.41

Company has 2 marketed drugs that It receives royalties from, 2 more that have an NDA pending ( New Drug Application) 1 drug In stage 3 clinical trials,7 In stage 2 clinical trials,5 In phase 1 clinical trials,and 7 In pre-clinical trials... They have some heavyweight partners as you can see below.
At Ligand, we believe collaboration is an important part of successful drug discovery and development. We have forged numerous valuable research and development alliances with global pharmaceutical companies that have ongoing clinical programs.
Pharmaceutical partnerships include the following companies and span programs in large market indications, such as muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases, anemia, asthma, rheumatoid arthritis and psoriasis.

•GlaxoSmithKline
•Wyeth
•Pfizer Inc.
•Bristol-Myers Squibb
•Schering-Plough
•Celgene
•Cephalon
•King Pharmaceuticals

Ligand Is Science
Our research and development programs—both within Ligand and with external partners—are built around our proprietary intracellular (IR) technology. Intracellar technology is the result of our ground-breaking work in the field of gene transcription. It is a powerful technology that has already generated numerous compounds which have advanced to late-stage clinical development.
Ligand Is Success
Ligand has the potential to realize profit streams from milestone and royalty revenues resulting from collaborations with pharmaceutical partners. Recently, we divested commercial assets, allowing us to focus on a business strategy that targets internal research and drug discovery that may provide future licensing opportunities. It seems to me that there are numerous drivers to push this stock In 2010. At a recent $1.93 per share I feel that the possibble upside outweighs the downside risks. Lots to like with such a diverse pipeline,and numerous high profile backers... TS

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar O5LDO (< 20) Submitted: 10/27/2009 3:36:06 PM : Outperform Start Price: $1.89 LGND Score: -4.09

Doubled my original investment into LDND today. Believe this is one biotech that will outperform in the coming years.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar jatt22 (< 20) Submitted: 9/15/2009 10:13:34 AM : Outperform Start Price: $2.26 LGND Score: -22.53

just bought in real P F

Report this Post 0 Comments | Reply | Permalink
View All 22 Pitches »

Leaderboard

Find the members with the highest scoring picks in LGND .

Score Leader

MoreCash4Me

MoreCash4Me (82.27) Score: +93.53

The Score Leader is the member with the highest score across all their picks in LGND .

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
anticitradeshort 26.33 4/20/2009 Underperform NS $2.77 -32.13% +30.38% +62.51
molbiolo < 20 1/4/2007 Underperform 1Y $8.20 -77.07% -17.04% +60.02
DavidHarvey2007 71.13 3/19/2007 Underperform 3M $7.59 -75.24% -16.20% +59.04
floridaoranges < 20 4/11/2007 Underperform 1Y $7.21 -73.93% -19.18% +54.75
MRT1212 92.72 10/5/2007 Underperform 3W $5.51 -65.88% -25.57% +40.31
shoutao 98.39 12/3/2007 Underperform NS $4.95 -62.02% -21.96% +40.06
ImmortalThanos 72.63 2/28/2008 Underperform 3Y $3.67 -48.77% -15.98% +32.79 1 Comment
MikeSmithTN 97.24 7/21/2008 Underperform NS $3.28 -42.68% -9.92% +32.76
OneBank < 20 7/21/2008 Underperform NS $3.28 -42.68% -9.92% +32.76
UncleSmitty < 20 7/14/2008 Underperform NS $3.19 -41.07% -9.17% +31.90
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackMerriman < 20 2/12/2009 Outperform NS $2.52 -25.40% +36.70% -62.10
TrackOppenheimer < 20 1/22/2009 Outperform NS $2.14 -12.15% +36.30% -48.45
TrackRodmanRen < 20 11/26/2008 Outperform NS $1.79 +5.03% +34.25% -29.23
TrackSusquehanna 72.81 12/7/2007 Outperform NS $4.81 -60.91% -23.63% -37.29
TrackJimCramer < 20 1/8/2007 Underperform 3W $8.53 -77.96% -17.00% +60.96
TrackBroadpoint.AmTech 71.99 9/11/2006 Outperform NS $7.98 -76.44% -9.39% -67.05

Featured Broker Partners